|
|
|
|
|
|
|
|
|
31.07.25 - 19:27
|
EQT completes sale of shares in Galderma Group AG (PR Newswire)
|
|
|
The sale resulted in aggregate gross proceeds of c. CHF 2.1 billion, of which EQT received c. CHF 555 million STOCKHOLM, July 31, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce the completion of the......
|
|
|
|
|
|
|
25.07.25 - 13:30
|
"Meisterschüsse" mit Mojmir Hlinka (Agfif International): "Riesenlob! Diese Ertragssaison wird brutal diversifiziert betrachtet" (BRN)
|
|
|
"Das Alte stürzt, es ändert sich die Zeit ..." - dieses Zitat aus Schillers "Wilhelm Tell" passt nicht nur gut zum Nationalfeiertag der "Eidgenossen" (am 1. August), sondern auch zum derzeitigen Weltgeschehen mit Disruption, Krieg und Zöllen: "Medizin, Chemie, Tourismus: Die Schweiz ist eine Exportnation", so Mojmir Hlinka von AGFIF International über die drohenden 10 % Strafzölle. Auch die Schweiz muss also durch die "hohle Gasse" und eine Einigung mit den USA erzielen, wobei Hlinka erwartet, dass der Franken immer stärker wird. Die Diversifikation im Depot erspart dem Anleger Enttäuschungen. So erfolgten nun auch Änderungen im Börsenradio-Echtgelddepot: "Wir haben Galderma und Accelleron gekauft. Und wir denken an weitere Gewinnmitnahmen bei Nvidia." Der kluge Anleger baut vor: "Ich sehe ein sehr rationales Verhalten der Investoren. Diese Ertragssaison wird brutal diversifiziert betrachtet." https://www.brn-ag.de/echtgelddepot...
|
|
|
|
|
|
|
|
|
24.07.25 - 07:06
|
Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025.
Record net sales of 2.448 billion USD, representing net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix
Double-digit growth in both International markets and the U.S., with strong performance across all product categories, including year-on-year growth of 9.8% for Injectable Aesthetics, 7.7% for Dermatological Skincare, and 26.9% for Therapeutic Dermatology at constant currency
Significant progress on the launch of new innovation, including Nemluvio® (nemolizumab) which continues to outperform, delivering 131 million USD in sales, the ongoing positive uptake of Relfydess™, now launched in 17 markets, and geographic expansion in Fillers & Biostimulators
Advancing leadership in science and education, supported by new long-term data on nemo...
|
|
|
|
|
|
|
|
|
|
|
01.07.25 - 07:03
|
Galderma Announces Departure of Its Chief Financial Officer (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization.
“We thank Thomas for his financial leadership and many contributions during his time at Galderma. He played a key role in establishing the financial discipline, operational readiness, and strategic clarity that will continue to guide us forward. We wish him every success in his next role and remain focused on further accelerating Galderma's strong growth – from category leadership to becoming a true powerhouse in dermatology.”
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA
Thomas Dittrich will remain with the company as Chief Financial Officer through Q2 2026 to ensure a seamless transition through the close of the 2025 fiscal year. A successor will be announced in d...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
